Selected transactions
Region
Exclusive Financial Advisor to Croma in constructing a 70-30% US- based exit JV to be majority- led by Korean Toxin specialist Hugel Corporation and concurrent Divestiture of its Canadian and Australian Subsidiaries to Hugel.
Exclusive Financial Advisor to Universkin for the completion of a strategic distribution agreement with Croma-Pharma GmbH and divestiture of a 5% stake to Croma.
Exclusive Financial Advisor in the acquisition of the outstanding equity of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company.
GSK Part of the Business Development Team which worked on the acquisition of dermatology specialty Pharma Stiefel.
Exclusive Advisor in Divestiture of US vaccine biotech Iomai Inc to Intercell AG, Vienna, Austria.
Exclusive Advisor in Divestiture of Oncology Molecular Diagnostics Medtech Oncotech to Exiqon.
Exclusive Advisor in Divestiture of Specialty Dermatology Company CollaGenex Pharmaceuticals (NASDAQ-listed CGPI) to Galderma SA.
Exclusive Financial Advisor in Acquisition of Excel-Tech, a developer of electro-diagnostic systems used in monitoring neurological problems.
Exclusive Financial Advisor in Divestiture of US instrumentation medtech NanoDrop Technologies to ThermoFisher.
Exclusive Financial Advisor in Divestiture of Esprit Pharma to Allergan.
Exclusive Financial Advisor in Divestiture of US biotech Renovis to Evotec AG, Hamburg in a reverse merger transaction.
Divestiture of Boehringer Ingelheim Do Brasil Química e Farmacêutica Ltda’s assets related to the Finn family of brands to Monte Cristalina SA.